Peramivir

...hospitalized flu patients. The Birmingham-based biotech firm's intravenous drug peramivir has met several significant milestones recently, including the filing of an application for regulatory approval in Japan. The shipment to the U.S....

In this article: HHS, Birmingham, U.S. Food and Drug Administration, and Japan

Peramivir works on the same principal as Tamiflu and Relenza, blocking an enzyme in flu viruses that enables it to flourish and spread, said Robert Bennett, executive director of business development and investor relations for BioCryst.

In this article: Relenza, U.S. Food and Drug Administration, Robert Bennett, Durham, Japan, and United States

...to include Taiwan. Under the terms of the agreement, BioCryst may receive future regulatory and commercial event milestone payments up to $102 million, as well as double digit royalty payments on product sales of peramivir. BioCryst retains...

In this article: Influenza, Japan, U.S. Food and Drug Administration, Taiwan, Forodesine, CTCL, Cancer, and T-cell lymphoma

...ill patients. Human clinical trials in the U.S. and Japan have called Peramivir safe and effective." But the FDA has not approved it. The agency has made at least a 20 exceptions, however, allowing "compassionate use" of the drug by...

In this article: H1N1, Google map, Relenza, Tamiflu, California and Nevada, Henry J. Kaiser Family Foundation, and FDA

...a conclusion. In September, BioCryst was awarded a $77.2 million contract modification by the HHS to complete development of i.v. peramivir and it subsequently initiated two Phase 3 studies of i.v. peramivir for the treatment of...

In this article: HHS, Revenue, Forodesine, United States, FDA, Amortization, and Pharmaceutical

...formulations of the drugs with some success. Additionally, BioCryst Pharmaceuticals of Birmingham, Ala, has been testing a third antiviral drug called peramivir, primarily in Japan. The President's Council of Advisors on Science and...

In this article: Relenza, GlaxoSmithKline, H1N1, Hodgkin's disease, Los Angeles Times, and Food and Drug Administration

...has shown activity against pandemic H1N1 swine flu origin viral strains. Peramivir has been studied in patients with complicated and uncomplicated influenza. BioCryst's partner, Shionogi & Co., Ltd. is currently preparing to file for...

In this article: Influenza, HHS, Pharmaceutical, U.S. Food and Drug Administration, Forodesine, CTCL, Cancer, and T-cell lymphoma

...flu drug sale Shionogi & Co. forecast that its experimental treatment peramivir will earn annual sales of about YEN5 billion in Japan on demand from hospitals for patients critically ill with influenza, including swine flu. Shionogi plans...

In this article: Relenza, Tamiflu, Fujifilm Holdings Corp., Daiichi Sankyo Co., Osaka, Japan, Crestor, and Cholesterol